Changeflow GovPing Healthcare & Life Sciences Amgen Design Patent: Handheld Drug Delivery Dev...
Routine Notice Added Final

Amgen Design Patent: Handheld Drug Delivery Device, USD1124318S1

Favicon for changeflow.com USPTO Patent Grants - Medical Devices (A61M)
Published
Detected
Email

Summary

The USPTO granted Amgen Inc. Design Patent USD1124318S1 for a handheld drug delivery device on April 28, 2026. The patent application (No. 29982645) was filed on January 7, 2025, and lists eight inventors: Austin Davis, Lars Eilertsen, David Lavmand Muller, Rasmus Ohlenschlaeger, Gregory Thomas Nowak, Kasper Poder, and Dylan Bourelle. The patent contains one claim and is classified under CPC codes related to drug delivery mechanisms including A61M 5/3156, A61M 5/31591, and related subcategories.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors USPTO Patent Grants - Medical Devices (A61M) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 59 changes logged to date.

Notice an inaccuracy or want this record removed? Email corrections@changeflow.com . We respond within 48 hours and honor reasonable requests. See our editorial standards .

What changed

The USPTO issued Design Patent USD1124318S1 to AMGEN INC. for a handheld drug delivery device. The patent was granted on April 28, 2026, with Application No. 29982645 filed January 7, 2025. Eight inventors are listed including Austin Davis, Lars Eilertsen, David Lavmand Muller, Rasmus Ohlenschlaeger, Gregory Thomas Nowak, Kasper Poder, and Dylan Bourelle. The design is classified under multiple CPC codes related to drug delivery devices.

Amgen Inc. now holds enforceable design rights for this handheld drug delivery device configuration in the United States. Competitors developing similar devices should review this patent to assess potential design-around requirements. The pharmaceutical and medical device industries should monitor Amgen's enforcement posture regarding this intellectual property.

Archived snapshot

Apr 28, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Handheld drug delivery device

Design USD1124318S1 Kind: S1 Apr 28, 2026

Assignee

AMGEN INC.

Inventors

Austin Davis, Lars Eilertsen, David Lavmand Muller, Rasmus Ohlenschlaeger, Gregory Thomas Nowak, Kasper Poder, Dylan Bourelle

CPC Classifications

A61M 5/3156 A61M 5/31591 A61M 5/3155 A61M 5/3157 A61M 5/24 A61M 5/31501 A61M 5/31551 A61M 5/31585

Filing Date

2025-01-07

Application No.

29982645

Claims

1

View original document →

Parties

Get daily alerts for USPTO Patent Grants - Medical Devices (A61M)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 28th, 2026
Instrument
Notice
Branch
Executive
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
USD1124318S1

Who this affects

Applies to
Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Design patent grant Drug delivery device
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Medical Devices Pharmaceuticals

Get alerts for this source

We'll email you when USPTO Patent Grants - Medical Devices (A61M) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!